Patient satisfaction health care resource utilization and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine

摘要

BackgroundEffects of galcanezumab, a monoclonal antibody against calcitonin gene-related peptide, on patient satisfaction, health care resource utilization (HCRU), and acute medication use were evaluated in a long-term, open-label study in patients with migraine.